VRCA
Verrica Pharmaceuticals Inc
4.10$
-1.7%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 94.4% | 95.0% | 92.6% | 91.0% | 85.6% | 94.5% | 93.6% | 94.1% | 88.7% | 90.3% | 84.5% | 90.6% | |
| 86.8% | 85.2% | 73.8% | 61.4% | 69.7% | 85.6% | 70.2% | 39.4% | 51.6% | 64.0% | 53.1% | 31.1% | |
| 86.8% | 85.2% | 73.8% | 61.4% | 69.7% | 85.6% | 70.2% | 39.4% | 51.6% | 64.0% | 53.1% | 31.1% | |
| 4.2% | 5.4% | 11.5% | 19.6% | 0.3% | 0.1% | 13.4% | 44.4% | 17.9% | 11.5% | 20.1% | 30.8% | |
| 0.3% | 1.3% | 3.8% | 5.2% | 7.8% | 4.5% | 5.8% | 6.4% | 5.6% | 4.7% | 5.1% | 7.5% | |
| 56.5% | 75.8% | 97.7% | 125.6% | 203.4% | 118.2% | 144.0% | 144.7% | 141.7% | 47.5% | 58.6% | 88.0% | |
| 11.7% | 20.9% | 29.2% | 38.6% | 63.9% | 53.6% | 69.7% | 74.7% | 70.7% | 34.9% | 41.8% | 62.3% | |
| 0.4% | 0.9% | 1.5% | 2.0% | 3.5% | 25.1% | 31.9% | 34.1% | 32.2% | 1.6% | 1.9% | 2.7% | |
| 2.0% | 3.0% | 3.8% | 2.2% | 2.9% | 3.5% | 3.4% | 5.9% | 3.9% | 4.4% | 5.7% | 4.5% | |
| 43.6% | 52.5% | 64.6% | 82.2% | 131.5% | 57.2% | 65.9% | 62.8% | 52.9% | – | – | – | |
| 43.5% | 24.2% | 2.3% | -25.6% | -103.4% | -18.2% | -44.0% | -44.7% | -41.7% | 52.5% | 41.4% | 12.0% | |
| -211.9% | -282.4% | -378.2% | -515.2% | -883.2% | -567.2% | -751.0% | -809.5% | -774.7% | -689.4% | -862.7% | -965.5% | |
| 4.7% | 5.7% | 7.0% | 8.9% | 14.2% | 12.4% | 22.5% | 24.3% | 23.2% | 22.6% | 54.9% | 59.2% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.